In selected patients with active acromegaly, long-term somatostatin analogue therapy has been demonstrated to effectively control GH and IGF-1 levels, induce tumor volume reduction and improve hypertension and cardiac performance [9, 10, 12]. This evidence concerns the gene GH1 and acromegaly.